Interleukin-1 Production by Mononuclear Cells and Natural Killer Cell Activity in Children with Acute Lymphoblastic Leukemia

  • A. Chybicka
  • J. Boguslawska-Jaworska
  • W. Budzyński
  • Cz. Radzikowski
  • W. Jaworski
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 34)


Interleukin 1 (IL-1) plays a major role in the response to infection, in inflammation, and in every immunological challenge. Over the past 10 years a variety of additional activities, especially of purified IL-1 on various target cells in vitro, has been reported [1]. As shown by Shirakawa et al. [2], IL-1 enhances also natural killer (NK) cell cytotoxic effect and proliferation. Expression of IL-2 receptors on NK cell surface can be regulated by IL-1 [3]. [4] Although IL-1 acts directly on many immunocompetent cells its role in malignant diseases has not yet been extensively explored [5]. We have previously reported apparent deficiency of IL-1 production by mononuclear cells of children with acute lymphoblastic leukemia (ALL) during the whole period of cytostatic therapy [6].


Hepatitis Lymphoma Leukemia Interferon Prostaglandin 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fibbe E, Schaafsma MR, Falkenburg FJ, Willmze R (1989) The biological activities of interleukin 1. Blut 59: 177CrossRefGoogle Scholar
  2. 2.
    Shirakawa F, Tanaka Y, Eto S, Suzuki H, Yodo Y, Yamashita U (1986) Effect of interleukin 1 on the expression of interleukin 2 receptor (TAC antigen) on human natural killer cells and natural killer-like cell line (YT cells). J Immunol 137: 551PubMedGoogle Scholar
  3. 3.
    Kataoka Y, Todo S, Morioka Y, Sugie K, Nakamura Y, Yodoi J, Imashuku S (1990) Impaired natural killer activity and expression of interleukin 2 receptor antigen in familial erythophagocytic lymphohistiocytosis. Cancer 65: 1937PubMedCrossRefGoogle Scholar
  4. 4.
    Peppoloni S, Bossu P, Boraschi D, Tagliabue A (1989) A short synthetic peptide fragment of human interleukin 113 increases both human and murine natural killer activity. Nat Immun Cell Growth Regul 8: 10–19PubMedGoogle Scholar
  5. 5.
    Herman JA, Kew MC, Rabson AR (1984) Defective interleukin-1 production by monocytes from patients with malignant diseases: interferon increasas IL-1 production. Cancer Immunol Immunother 16: 182–185PubMedCrossRefGoogle Scholar
  6. 6.
    Chybicka A, Boguslawska-Jaworska J (1990) Interleukin 1 production in childhood acute lymphoblastic leukemia during chemo-and radiotherapy according to BFM (BerlinFrankfurt-Munster) protocol. In: Büchner T et al. Acute leukemias II. Berlin Heidelberg New York 33: 72 (Hematology and blood transfusion)Google Scholar
  7. 7.
    Frydecka I (1985) Natural killer cell activity during the course of disease in patients with Hodgkin’s disease. Cancer 56: 2799PubMedCrossRefGoogle Scholar
  8. 8.
    Pross HF, Maroun JA (1984) The standardisation of NK cell assays for use in studies of biological response modifiers. J Immunol Methods 68: 235PubMedCrossRefGoogle Scholar
  9. 9.
    Zimecki M, Wieczorek Z (1987) IL-1 decreases the level of thymocytes forming rosettes with autologous erythrocytes, a new method of determination of I1–1 activity. Arch Immunol Ther Exp (Warsz) 355: 371Google Scholar
  10. 10.
    Migliorati G, Cannarile L, D’Adamio L, Herberman RB, Riccardi C (1987) Interleukin 1 auguments the interleukin 2 dependent generation of natural killer cells from bone marrow precursor. Nat Immun Cell Growth Regul 6: 306PubMedGoogle Scholar
  11. 11.
    Pross HF, Baines M (1987) Alterations in natural killer cell activity in tumor-bearing hosts. In: Herberman RB, et al. (eds) Immune responses to metastases. CRC Press, Boca Raton, p 57Google Scholar
  12. 12.
    Lange A, Flad HD, Jack A, Ulmer AJ (1986) Effect of human recombinant interleukin 2 on natural killing of low density percoll fraction cells. Immunol Lett 12: 243–250PubMedCrossRefGoogle Scholar
  13. 13.
    Douer D, Shaked N, Ramot B (1987) Normal natural killer activity in Hodgkin’s disease patients in remission. Clin exp Immunol 69: 660–667PubMedGoogle Scholar
  14. 14.
    Mehta BA, Satam MN, Advani H, Nadkarin JJ (1989) In vitro modulation of natural killer cell activity in non-Hodgkin’s lymphoma patients after therapy. Cancer Immunol Immunother 28: 148–152PubMedCrossRefGoogle Scholar
  15. 15.
    Tanaka Y (1981) Natural killer NK activity in children with acute lymphoblastic leukemia. Hiroshima J Med Sci 30: 127PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • A. Chybicka
    • 1
  • J. Boguslawska-Jaworska
    • 1
  • W. Budzyński
    • 2
  • Cz. Radzikowski
    • 2
  • W. Jaworski
    • 3
  1. 1.Department of Hematology and OncologyMedical AcademyWroclawPoland
  2. 2.Department of Tumor ImmunologyInstitute of Immunology and Experimental Therapy Polish Academy of ScienceWroclawPoland
  3. 3.Department of Children SurgeryMedical AcademyWroclawPoland

Personalised recommendations